Uusi ravimeetodeid on depressiooni raviks tulnud ja tulemas. Muidugi pole kõik kohe kättesaadav, aga siiski pole tulevik nii tume.
Meil on Sensuseski olemas paar meetodit, kui muu pole aidanud:
https://www.sensus.ee/transkraniaalne-m ... mulatsioon ja ka
https://www.sensus.ee/transkraniaalne-a ... lisvooluga
Lisaks netist:
New depression treatments focus on rapid-acting solutions for treatment-resistant cases, including ketamine/esketamine, SAINT (accelerated TMS), and new neurosteroid meds. These therapies provide relief in days rather than weeks by targeting different pathways, such as glutamate or GABA receptors, and using AI-guided brain stimulation.
Key New & Emerging Treatments
SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy): An intensive, FDA-cleared, MRI-guided form of TMS that provides high remission rates (80-90%) in as little as 5 days.
Ketamine & Esketamine: Fast-acting intravenous ketamine or intranasal esketamine (Spravato) for rapid relief of severe or treatment-resistant depression by targeting NMDA receptors.
Zuranolone (Zurzuvae): A fast-acting, oral neuroactive steroid approved for postpartum depression that modulates GABA-A receptors, according to LifeStance Health.
Exxua (gepirone): Recently FDA-approved, this is the first oral selective 5-
receptor agonist for major depressive disorder, designed with fewer sexual/weight gain side effects, as mentioned by The Online GP.
AXS-05: A novel combination of dextromethorphan and bupropion that acts on the NMDA receptor, note PubMed Central (PMC).
Technological Advancements
Intermittent Theta Burst Stimulation (iTBS): A form of TMS that can be delivered in roughly 3 minutes rather than 30-minute sessions, as described by Mayo Clinic.
At-home Wearable Brain Stimulation: Research is advancing into self-administered neurostimulation devices for depression Management, according to LifeStance Health